Cidara Therapeutics, Inc.
CDTX
Classifica tra le azioni
#3183
Cidara Therapeutics, Inc. is a biotechnology company specializing in the... Cidara Therapeutics, Inc. is a biotechnology company specializing in the creation, advancement, and commercialization of extended-duration anti-infective drugs. Their mission targets the prevention and treatment of infectious diseases and certain cancers within the U.S. Their primary therapeutic candidate, rezafungin acetate, is an innovative echinocandin antifungal designed to combat and avert severe fungal infections such as candidemia and invasive candidiasis, conditions known for their high fatality rates. Additionally, Cidara utilizes its Cloudbreak platform to engineer conjugated therapies aimed at preventing and treating influenza as well as various other viral illnesses, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), and SARS-CoV-2, the pathogen behind COVID-19. Originally incorporated in 2012 as K2 Therapeutics, Inc., the company adopted its current name, Cidara Therapeutics, Inc., in July 2014. Its operations are headquartered in San Diego, California.
Prezzo delle azioni
$221.38
Ultima sincronizzazione: 2026-01-08
Capitalizzazione di mercato
$5.61B
Variazione (1 giorno)
0.00%
Variazione (1 anno)
120.15%
Paese
US
Scambia Cidara Therapeutics, Inc. (CDTX)
Categoria
Healthcare
Ricavi di Cidara Therapeutics, Inc. (CDTX)
Ricavi nel Sep 2025 TTM: 0.00
Secondo gli ultimi rapporti finanziari di Cidara Therapeutics, Inc., i ricavi attuali dell'azienda (TTM) sono pari a 0.00. Nel 2023, l'azienda ha registrato ricavi di $23.28M una diminuzione rispetto a i ricavi dell'anno 2022, che erano pari a $64.45M. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Cidara Therapeutics, Inc. da 2012 a 2026
Ricavi alla fine di ogni anno
| Anno | Ricavi | Cambia |
|---|---|---|
| 2026 (TTM) | 0.00 | -100.00% |
| 2024 | $1.28M | -94.52% |
| 2023 | $23.28M | -63.87% |
| 2022 | $64.45M | 30.01% |
| 2021 | $49.57M | 310.81% |
| 2020 | $12.07M | -42.30% |
| 2019 | $20.92M | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | 0.00% |
| 2012 | 0.00 | 0.00% |
Ricavi di aziende simili o concorrenti
| Azienda | Ricavi | Differenza nei ricavi | Il paese |
|---|---|---|---|
| $12.62B | - |
US
|
|
| $2.23B | - |
US
|
|
| $15.74B | - |
AU
|
|
| - | - |
CH
|
|
| $6.02B | - |
NL
|
